Trial Profile
Single center, randomized, double-blind, placebo controlled phase Ib Study to Evaluate tolerability, PK/PD of three doses of Seraprevir in subjects with chronically infected hepatitis C virus
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Jul 2017
Price :
$35
*
At a glance
- Drugs Seraprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Ginkgo Pharma
- 23 Apr 2017 Status changed from recruiting to active, no longer recruiting, according to the results Results presented at The International Liver Congress 2017
- 29 Apr 2016 New trial record